Kymera Therapeutics, Inc. (KYMR) Earnings
Kymera Therapeutics, Inc. is expected to report next earnings on August 10, 2026 (in NaN days), with a consensus EPS estimate of $-0.73. KYMR has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -7.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $-0.89 | $-0.71 | +20.2% | $34M | +315.7% |
| Feb 26, 2026 | $-0.77 | $-1.03 | -33.9% | $3M | -80.7% |
| Nov 4, 2025 | $-0.71 | $-0.90 | -26.8% | $3M | -80.9% |
| May 9, 2025 | $-0.92 | $-0.82 | +10.9% | $22M | +78.5% |
| Feb 27, 2025 | $-0.76 | $-0.88 | -15.8% | $7M | -55.7% |
| Oct 31, 2024 | $-0.83 | $-0.82 | +1.2% | $4M | -75.4% |
| May 2, 2024 | $-0.73 | $-0.69 | +5.5% | $10M | -24.9% |
| Feb 22, 2024 | $-0.44 | $-0.25 | +43.2% | $48M | +14.1% |
| Nov 2, 2023 | $-0.73 | $-0.90 | -23.3% | $5M | -70.4% |
| Aug 3, 2023 | $-0.70 | $-0.67 | +4.3% | $17M | +17.4% |
| May 4, 2023 | $-0.69 | $-0.70 | -1.4% | $9M | -33.1% |
| Feb 23, 2023 | $-0.57 | $-0.60 | -5.3% | $16M | -26.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 30, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Marked 10-year anniversary, stepping into new chapter with strong foundation. Built unique capabilities like heat-finding approach, target selection strategies, and early clinical studies. - Focused on wholly owned programs like KT621, KT579. KT621 on track for enrollment completion in atopic dermatitis Broaden2 study this year, data expected mid-2027; asthma breadth study readout end 2027. - KT579 phase one study in healthy volunteers to report data in second half 2026, aiming to demonstrate safe degradation and biology translation. - Gilead collaboration: Gilead advancing KT200, a CDK2 molecular glue, which could enter clinic next year. - STAT6 program: KT621 phase 1b broadened data presented at AAD, early data shows potential in AD, actively enrolling phase 2b studies in AD and asthma.
Guidance
- KT621: Expect to complete enrollment in atopic dermatitis Broaden2 study this year, data mid-2027; asthma breadth study readout end 2027. - KT579: Expect to report healthy volunteer data in second half 2026. - Gilead partnership: KT200 expected to enter clinic as early as next year. - Sanofi: Expect Sanofi to advance KT485 into Phase 1 testing this year with milestone upon dosing first healthy volunteer.
Segment performance
Collaboration revenue in the first quarter of 2026 was $34.4 million attributable to Gilead partnership. R\u0026D expense for the quarter was $98.2 million, with adjusted cash R\u0026D spend of $89.6 million (18% increase from Q4 2025). G\u0026A spending was $20.4 million, with adjusted cash G\u0026A spend of $13 million (30% increase from Q4 2025). Ended March with a cash balance of $1.55 billion.
Analyst Q&A
Q: Asked about IRF5 data on healthies and how biomarker pathway modulation translates clinically;
A: Discussed based on preclinical data, expecting 50%-80% modulation, and translation to clinical benefit.
Q: Asked about IRF5 degradations needed in lupus patients and translation from healthy volunteers;
A: Explained dose and exposure to achieve relevant degradation, expecting translation from healthy to patients.
Q: Asked about initial enrollment in Broaden 2 and baseline characteristics;
A: Stated not to comment on baseline until study completion.
Q: Asked about technology advances for CDK2 and more pipeline molecules;
A: Explained challenges with CDK2, use of molecular glues, and expectation of more pipeline molecules.
Q: Asked about BSA data at AAD and dose response;
A: Stated error bars overlap, comparable activity across doses.
Q: Asked about Stat6 program and excitement for oral aspect;
A: Explained degraders' differentiation from inhibitors, and focus on mobilizing patients not on advanced therapies.
Q: Asked about inclusion of adolescents in trial and criteria change;
A: Explained inclusion of adolescents to study in younger population.
Q: Asked about enrollment progress in AD and asthma studies;
A: Stated studies on track, will communicate when enrollment complete.
Q: Asked about contrast of KT621 with IL-23 space;
A: Explained opportunity in AD being greater than in psoriasis.
Q: Asked about IRF5's mechanism in IBD and combination therapies;
A: Explained IRF5's control of multiple pathways in IBD and potential for combination.
Q: Asked about population on sidelines for KT621;
A: Explained large number of patients not on advanced systemic therapies.
Q: Asked about 621 program for asthma and go-no-go decisions;
A: Stated waiting for phase three asthma data to determine doses for other indications.
Q: Asked about dose response range for 621;
A: Stated thinking about dose selection for mechanistic and regulatory reasons.
Q: Asked about side effects for 579;
A: Stated preclinical data shows no meaningful adverse events expected.
Q: Asked about efficacy needed for KT621 to mobilize patients;
A: Stated less than biologic-like efficacy enough to mobilize patients